Abstract
Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors. A side effect of sorafenib is the occurrence of cutaneous squamous tumors. Here we describe three patients with a history of sorafenib treatment for advanced radioactive iodine refractory papillary thyroid cancer (two with a BRAF c.1799 T > A and one carrying a rare c.1799-1801het_delTGA mutation) who presented with secondary non-cutaneous lesions. The first patient was diagnosed with a squamous cell carcinoma (SCC) of the tongue, the second patient with a primary adenocarcinoma of the lung, and the third with a SCC originating from the cricoid. Secondary analysis was required to show that the latter two presentations were in fact recurrent thyroid cancer. These findings suggest that drugs such as sorafenib may induce metaplasia/clonal divergence of metastatic thyroid cancer and thus cause diagnostic misclassification. Furthermore, sorafenib is potentially involved in the tumorigenesis of secondary non-cutaneous SCC. These observati...Continue Reading
References
Feb 3, 2000·Journal of the National Cancer Institute·P TherasseS G Gwyther
Jun 19, 2008·Archives of Dermatology·David S HongRazelle Kurzrock
Feb 14, 2009·Clinical Genitourinary Cancer·Zita DubauskasNizar M Tannir
Aug 8, 2009·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Kathleen J SmithHenry G Skelton
Sep 24, 2009·European Journal of Endocrinology·Hendrieke HoftijzerJohannes W Smit
Dec 5, 2009·The Journal of Molecular Diagnostics : JMD·Ronald van EijkTom van Wezel
Dec 22, 2010·Archives of Dermatology·Amanda K RaymondKelly Carter Nelson
Mar 19, 2011·International Journal of Dermatology·Victoria L WilliamsDavid J Stewart
Nov 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean Philippe ArnaultCaroline Robert
Jan 20, 2012·The New England Journal of Medicine·Fei SuRichard Marais
May 9, 2012·Annals of Laboratory Medicine·Mi-Ae JangJong-Won Kim
Aug 25, 2012·European Journal of Endocrinology·T C SchneiderE Kapiteijn
Nov 9, 2012·The New England Journal of Medicine·Margaret K CallahanPaul B Chapman
Apr 18, 2013·Thyroid : Official Journal of the American Thyroid Association·Sang Ryung LeeChang Suk Kang
Nov 6, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Miles C AndrewsJonathan Cebon
Nov 21, 2013·Experimental and Therapeutic Medicine·Yong-Wha Lee
Apr 29, 2014·Lancet·Marcia S BroseUNKNOWN DECISION investigators